These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


355 related items for PubMed ID: 11197987

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
    Kole AC, Nieweg OE, Pruim J, Paans AM, Plukker JT, Hoekstra HJ, Schraffordt Koops H, Vaalburg W.
    J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
    [Abstract] [Full Text] [Related]

  • 3. Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer.
    Kim BS, Sung SH.
    Ann Nucl Med; 2012 Feb; 26(2):175-83. PubMed ID: 22139552
    [Abstract] [Full Text] [Related]

  • 4. Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma.
    Ekmekcioglu O, Aliyev A, Yilmaz S, Arslan E, Kaya R, Kocael P, Erkan ME, Halac M, Sonmezoglu K.
    Nucl Med Commun; 2013 Nov; 34(11):1055-67. PubMed ID: 24025919
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary.
    Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, Kotsuji F.
    Int J Cancer; 2004 May 10; 109(6):926-32. PubMed ID: 15027127
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.
    Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H.
    Jpn J Clin Oncol; 2008 Apr 10; 38(4):250-8. PubMed ID: 18407934
    [Abstract] [Full Text] [Related]

  • 11. Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors.
    Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T.
    Int J Clin Oncol; 2010 Dec 10; 15(6):588-93. PubMed ID: 20809217
    [Abstract] [Full Text] [Related]

  • 12. Correlation of Glut-1 glucose transporter expression with.
    Higashi K, Ueda Y, Sakurai A, Wang XM, Xu L, Murakami M, Seki H, Oguchi M, Taki S, Nambu Y, Tonami H, Katsuda S, Yamamoto I.
    Eur J Nucl Med; 2000 Dec 10; 27(12):1778-85. PubMed ID: 11189940
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.
    Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, Cook JB, Larson S.
    J Nucl Med; 2010 Apr 10; 51(4):543-50. PubMed ID: 20237034
    [Abstract] [Full Text] [Related]

  • 18. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
    Zhao Z, Yoshida Y, Kurokawa T, Kiyono Y, Mori T, Okazawa H.
    J Nucl Med; 2013 Apr 10; 54(4):499-506. PubMed ID: 23471314
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 18.